BioMedAI · Agent Set 2
Drug Design
Intelligence Agents
DDIA takes validated targets from TDIA and applies generative AI to design, screen, and optimize candidate molecules — reasoning over structure-activity relationships, ADMET profiles, and synthesis feasibility.
In Development
70%
Stage 2
Follows TDIA target research output
TDIA — Live
DDIA — In Dev
DDIA is Stage 2 of the BioMedAI pipeline — it receives target validation outputs from TDIA and applies generative AI to molecule design.
Design Workflow
From Validated Target to Lead Candidate
DDIA agents orchestrate the full small molecule and biologics design loop with continuous optimization.
1. Target Input
Input requested drug targets and user constraints.
2. Molecule Generation
Generate candidate molecules optimized for binding affinity and selectivity.
3. Developability Screening
Each candidate is scored and filtered for developability prediction.
4. Lead Ranking
Top candidates are ranked by multi-parameter optimization and synthesis feasibility score.
Capabilities
What DDIA Delivers
In Development
Get Early Access to DDIA
We're working with select biopharma teams to co-develop DDIA's capabilities. If you have a drug design challenge, we'd like to hear from you.
Book a Discovery CallStart with TDIA While DDIA Launches
TDIA is live today. Get your target research automated now — and be first in line when DDIA ships.